SOUTH PLAINFIELD, N.J., June 26 /PRNewswire/ -- PTC Therapeutics, Inc.
(PTC), a biopharmaceutical company focused on the discovery, development
and commercialization of small-molecule drugs targeting
post-transcriptional control mechanisms, today announced the appointment of
Manal Morsy, M.D., Ph.D. as Vice President of Regulatory Affairs. In this
role, Dr. Morsy will be responsible for leading PTC's regulatory affairs
activities for PTC124, PTC299, and future clinical programs.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )
"We are thrilled to welcome Dr. Morsy to our management team. Her broad
experience in leading successful regulatory strategies will be invaluable
to PTC as we continue the rapid advancement of our clinical programs," said
Stuart Peltz, Ph.D., President and Chief Executive Officer of PTC
Therapeutics. "Dr. Morsy adds critical expertise in the regulatory arena as
we expand our capabilities and move toward our goal of becoming a fully
integrated biopharmaceutical company."
"I am excited to join the PTC Therapeutics team. The Company's clinical
pipeline has tremendous potential to address significant areas of unmet
medical need, and I am looking forward to guiding the regulatory strategies
to advance the registration and commercialization plans for these novel and
potentially life-changing compounds to patients," commented Dr. Morsy.
Prior to joining PTC, Dr. Morsy spent three years at Tibotec / J&J,
most recently serving as Senior Director, Global Regulatory Affairs. There
she was responsible for global regulatory activities for the company's
pediatric development programs and the tuberculosis program. Previous to
her tenure at Tibotec, Dr. Morsy served as Director of Worldwide Regulatory
Affairs for Merck & Co., where she supported new regulatory filings in the
US and abroad, as well as supplemental filings for previously approved
products.
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery,
development and commercialization of orally administered, proprietary,
small-molecule drugs that target post-transcriptional control processes.
Post-transcriptional control processes regulate the rate and timing of
protein production and are of central importance to proper cellular
function. PTC's internally-discovered pipeline addresses multiple
therapeutic areas, including genetic disorders, oncology and infectious
diseases. In addition, PTC has developed proprietary technologies and
extensive knowledge of post-transcriptional control processes that it
applies in its drug discovery and development activities, including the
Gene Expression Modulation by Small-molecules (GEMS) technology platform,
which has been the basis for collaborations with leading pharmaceutical and
biotechnology companies such as Pfizer, CV Therapeutics and
Schering-Plough. For more information, please visit the Company's website
at http://www.ptcbio.com.
SOURCE PTC Therapeutics, Inc.
 back to top
Related links:
http://www.ptcbio.com/
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Jane Baj of PTC Therapeutics, Inc.,
+1-908-222-7000 x167, jbaj@ptcbio.com; or Sheryl Seapy of Pure
Communications, +1-949-608-0841, sheryl@purecommunicationsinc.com
|
